Lupus érythémateux disséminé. Responsabilité de la carbamazépine. À propos d'un cas

Ghorayeb, Imad; Sériès, C.; Loiseau, P; Guez, S.; Boulanger-Bessout, J; Dale, C.H.; Malterre, L.

doi:10.1016/0248-8663(96)86451-4

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a greater severity of the clinical manifestations, the impossibility of abruptly withdraw the inducing drug, and the fact that the diagnosis is usually a posteriori, may make the treatment with corticosteroids, synthetic anti-malarials, or immunosuppressants necessary. In exceptional cases, it may be necessary to weigh up the risks and benefits before withdrawing an effective drug if there are no other effective alternatives, as was the case in which the CBZ was continued as it was considered as the only really effective drug for the diseases treated (23). The majority of DILE symptoms will disappear in a few weeks after withdrawing the inducing drug, although in the occasional patient it may take up to 1 year to completely recover.…”

Section: Discussionmentioning

confidence: 99%

Carbamazepine-induced systemic lupus erythematosus: A case-based review

Álvarez-Lario¹,

Bártulos-Iglesias²,

Colazo-Burlato³

et al. 2019

Eur J Rheumatol

View full text Add to dashboard Cite

A case of carbamazepine-induced systemic lupus erythematosus (CBZ-DILE) is presented, along with a literature review, with the aim to define the clinical and serological characteristics of this group, and compare them with systemic lupus erythematosus (SLE) triggered by other drugs (DILE). A 31-year-old woman presented with a 6-month history of hand arthritis and nasal ulcers. She had been diagnosed with epilepsy at 12 years of age and had continued treatment with carbamazepine (CBZ) for the past 18 years with excellent clinical control. Laboratory data revealed antinuclear antibodies (ANA) positive to a titer of 1/1280, and positive anti-nucleosome antibodies. The patients’ clinical symptoms disappeared after the CBZ discontinuation and did not reappear during the 1-year follow-up period. A search was made in the PubMed/Medline database of the (CBZ-DILE) published cases. A total of 26 cases of CBZ-DILE were found in the search. CBZ-DILE cases are characterized by variable latency periods that often last for years and are not related to the dose of CBZ. Most frequent clinical findings of CBZ-DILE in patients are arthralgia/arthritis, mucocutaneous manifestations, constitutional symptoms, and pleuritis or pericarditis. The renal involvement has not been reported in CBZ-DILE. Antihistone antibodies were observed less frequently, and anti-dsDNA antibodies were observed more frequently than in the “classic” DILE. The ANA remained positive in over 60% of cases during the follow-up after withdrawal. The CBZ-DILE has significant clinical and laboratory manifestations that distinguish it from classic DILE or idiopathic SLE.

show abstract

Section: Discussionmentioning

confidence: 99%